Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Return on Assets (2016 - 2025)

Historic Return on Assets for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 1.17%.

  • Sangamo Therapeutics' Return on Assets rose 1500.0% to 1.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.17%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 0.73% for FY2024, which is 300.0% down from last year.
  • As of Q3 2025, Sangamo Therapeutics' Return on Assets stood at 1.17%, which was up 1500.0% from 0.69% recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Return on Assets peaked at 0.14% during Q1 2021, and registered a low of 2.25% during Q2 2024.
  • For the 5-year period, Sangamo Therapeutics' Return on Assets averaged around 0.76%, with its median value being 0.52% (2023).
  • In the last 5 years, Sangamo Therapeutics' Return on Assets tumbled by -19800bps in 2024 and then surged by 15600bps in 2025.
  • Over the past 5 years, Sangamo Therapeutics' Return on Assets (Quarter) stood at 0.24% in 2021, then crashed by -39bps to 0.33% in 2022, then plummeted by -303bps to 1.34% in 2023, then soared by 31bps to 0.92% in 2024, then dropped by -27bps to 1.17% in 2025.
  • Its Return on Assets was 1.17% in Q3 2025, compared to 0.69% in Q2 2025 and 0.85% in Q1 2025.